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Abstract
Introduction An emerging hypothesis suggests that cytokines
could play an important role in cancer as potential modulators of
angiogenesis and leucocyte infiltration.
Methods A novel multiplexed flow cytometry technology was
used to measure the expression of 17 cytokines (IL-1β, IL-2, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 [p70], IL-13, IL-17,
granulocyte colony-stimulating factor [CSF], granulocyte-
macrophage CSF, IFN-γ, monocyte chemoattractant protein
[MCP]-1, macrophage inflammatory protein [MIP]-1β, tumour
necrosis factor [TNF]-α) at the protein level in 105 breast
carcinoma. B lymphocyte, T lymphocyte and macrophage levels
were determined by immunohistochemistry.
Results Fourteen of the 17 cytokines were expressed in breast
carcinoma, whereas only nine cytokines could be detected in
normal breast. Most cytokines were more abundant in breast
carcinoma than in normal breast, with IL-6, IL-8, granulocyte
CSF, IFN-γ, MCP-1 and MIP-1β being very abundant. IL-2, IL-6,
IL-8, IL-10, IFN-γ, MCP-1, MIP-1β and TNF-α, and to a lesser
extent IL-1β and IL-13 exhibited levels of expression that were
inversely correlated to oestrogen receptor and progesterone
receptor status. Most cytokines were not correlated with age at
cancer diagnosis, tumour size, histological type, or lymph node
status. However, IL-1β, IL-6, IL-8, IL-10, IL-12, MCP-1 and MIP-
1β were more abundant in high-grade tumours than in low-grade
tumours. In addition, IL-8 and MIP-1β were expressed to a
greater degree in HER2-positive than in HER2-negative
patients. The expression of most of the studied cytokines was
correlated to levels of activator protein-1, which is known to
regulate numerous cytokines. Overexpression of MCP-1 and
MIP-1β were linked to B lymphocyte, T lymphocyte and
macrophage infiltration, whereas high levels of IL-8 were
correlated with high macrophage content in tumour. Moreover,
IL-8 positive tumours exhibited increased vascularization.
Conclusion We found that multiple cytokines were
overexpressed in oestrogen receptor negative breast
carcinoma, and that the three major cytokines – MCP-1, MIP-1β
and IL-8 – were correlated with inflammatory cell component,
which could account for the aggressiveness of these tumours.
Introduction
Breast cancer represents the leading cause of cancer death
among women in developed countries [1]. Among the various
prognostic factors, lack of oestrogen receptor (ER) has con-
sistently been associated with poorer prognosis [2]. Most
human breast cancers express ER-α, and the presence of this
receptor is generally considered an indication of hormone
dependence [3]. In addition to ER-α, cytokines are now
AP = activator protein; ER = oestrogen receptor; G-CSF = granulocyte colony-stimulating factor; GM-CSF = granulocyte-macrophage colony-stim-
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emerging as factors that are potentially involved in breast car-
cinogenesis [4,5]. Cytokines constitute a diverse group of pro-
teins that include haematopoietic growth factors, interferons,
lymphokines and chemokines [6].
Cytokines are produced by many cell populations, but the pre-
dominant suppliers are T-helper (Th) cells and macrophages.
Th cells have two important functions: to stimulate cellular
immunity and inflammation, and to stimulate B cells to produce
antibody. Two functionally distinct subsets of Th cells (Th1
and Th2) secrete cytokines that promote these different activ-
ities. Th1 cells produce IL-2 and IFN-γ, which activate cyto-
toxic lymphocytes and macrophages to stimulate cellular
immunity and inflammation [7]. Th2 cells secrete IL-4 and IL-5,
which stimulate antibody production by B cells.
It has become evident that cancer tissues also produce
cytokines [4,8]. Numerous studies have analyzed the expres-
sion of diverse cytokines independently in breast cancer, but
only a few have examined the profile of a group of cytokines at
the tumour site. In the present study we screened 17 members
of the cytokine family (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
10, IL-12 [p70], IL-13, IL-17, granulocyte colony-stimulating
factor [G-CSF], granulocyte-macrophage colony-stimulating
factor [GM-CSF], IFN-γ, monocyte chemoattractant protein
[MCP]-1, macrophage inflammatory protein [MIP]-1β and
tumour necrosis factor [TNF]-α) in breast cancer tissues. We
found that most cytokines were overexpressed in breast can-
cer compared with normal tissues. IL-2, IL-6, IL-8, IL-10, INF-γ,
MCP-1, MIP-1β, TNF-α, IL-1β and IL-13 were inversely corre-
lated with ER and progesterone receptor (PR) status. Most of
the cytokines were not correlated with patient age, tumour
size, histological type, or lymph node status. IL-1β, IL-6, IL-8,
IL-10, IL-12, MCP-1 and MIP-1β were abundant in high-grade
tumours. Moreover, IL-8 and MIP-1β were linked to HER2
expression. In addition, IL-8 positive tumours exhibited greater
vascularization. Robust expression of IL-8, MCP-1 and MIP-1β
was correlated with a strong inflammatory cell component.
Materials and methods
Patients and samples
Breast tumour surgical specimens were selected from the files
of the Pathology Department (CRLC Val d'Aurelle) tumour
bank. Breast biopsies were from surgical waste; they were not
formal samples taken for diagnosis and they did not undergo
genetic evaluation. The samples were selected by a patholo-
gist from fresh surgical specimens immediately after resection.
For each sample, a twin sample from the same tissue was
taken at the same time, embedded in paraffin and evaluated to
ensure that the tissue was indeed tumourous. When possible,
a sample of normal breast tissue in the vicinity of the tumour
was also taken. All of the patients had primary unilateral, non-
metastatic breast carcinoma, and complete clinical, histologi-
cal and biological information was available for all of them. The
clinical and pathological characteristics of the patients are
given in Additional file 1. The tumours included invasive carci-
noma, mainly ductal and lobular, and other rare subtypes
(mixed ductal and lobular carcinoma, medullary carcinoma and
apocrine carcinoma). The tumours were graded according to
the modified Nottingham SBR system [9] and categorized
according to the sixth edition of the AJCC (American Joint
Committee on Cancer) Cancer Staging Manual for pTNM
staging. ER-α, progesterone receptor (PR) and HER2 status
were determined at the protein level by immunohistochemistry.
When equivocal, HER2 results were confirmed by fluores-
cence in situ hybridization.
Immunohistochemistry and fluorescence in situ 
hybridization analysis
Representative tissue sections from cases of invasive breast
carcinoma were fixed in 10% formalin or in alcohol-formalin-
acetic acid and embedded in paraffin. Sections from each
case were deparaffinized, rehydrated and subsequently sub-
jected to heat induced antigen retrieval by immersing them,
depending on the antibody, either in a water bath with a
sodium citrate buffer (pH 6) or an EDTA buffer (pH 8). Immu-
nohistochemistry was performed using a Dako autostainer
(Dako, Glostrup, Denmark). Then, the sections were incubated
with the following primary antibodies: ER-α (clone 6F11, mon-
oclonal; Novocastra, Newcastle-Upon-Tyne, UK), PR (clone
PgR636, monoclonal; DakoCytomation, Glostrup, Denmark)
and HER 2 (A0485, polyclonal; DakoCytomation). They were
respectively used at 1:50, 1:100 and 1:1500 dilutions with an
incubation time of 30 min. Antibody was localized using the
LSAB® 2 Detection System (Dako). Diaminobenzidine (Dako)
was used as the chromogen and the sections were lightly
counterstained with haematoxylin. ER and PR expression was
considered positive when at least 10% of invasive tumoural
cells exhibited nuclear staining, regardless of intensity. For
HER2, the immunohistochemical score was assigned accord-
ing to the Herceptest® scoring system (0 = absence of mem-
branous staining or fewer than 10% positive cells; 1+ = more
than 10% stained cells with weak and incomplete membra-
nous staining; 2+ = more than 10% stained cells with weak or
moderate complete membranous staining; and 3+ = more
than 10% stained cells with strong and complete membra-
nous staining). A case was considered to be HER2 overex-
pressing if it scored 3+. A case scoring 2+ was considered to
be HER2 overexpressing only if fluorescence in situ hybridiza-
tion analysis using the PathVysion HER-2 Probe Kit (Vysis,
Downer's Grove, IL, USA) revealed HER2 gene amplification.
The inflammatory cell component was evaluated in a subset of
10 tumours exhibiting high levels of IL-8 and 10 tumours with
low IL-8 content using CD3 (T-lymphocyte lineage), CD20 (B-
lymphocyte lineage) and CD68 (macrophages) antibodies.
The intensity of each pattern of inflammatory infiltrate was
graded as absent (0), minimal (1), moderate (2), or marked (3).
The staining result for each antibody was scored by two inves-
tigators who were blinded as to the IL-8 status of the patients.Available online http://breast-cancer-research.com/content/9/1/R15
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Vessels were assessed within the invasive carcinoma in
CD31-stained sections. The most vascular areas were identi-
fied by examination at low power (× 40 magnification). The
number of clusters or single cells stained for CD31 was
recorded from the three most vascular × 400 fields (0.18 mm2
each) and the vascular density (number of vessels/mm2) was
calculated.
Protein extract preparation
Biopsies were first crushed in liquid nitrogen. The powder was
then resuspended in TEG (10 mmol/l Tris-HCl [pH 7.4], 1.5
mmol/l EDTA and 10% glycerol) containing protease inhibi-
tors (5 μg/ml aprotinin, leupeptin and pepstatin A, and 0.1
mmol/l phenylmethylsulfonyl fluoride). The mixture was then
sonicated and the cellular debris was pelleted by centrifuga-
tion at 13,000 g for 20 minutes at 4°C in microfuge tubes.
Cytokine multiplexed bioplex assay
A panel of 17 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12 [p70], IL-13, IL-17, G-CSF, GM-CSF, IFN-γ,
MCP-1, MIP-1β, TNF-α) was measured in duplicate using the
bioplex cytokine multiplexed assay (BioRad, Hercules, CA,
USA), in accordance with the manufacturer's instructions
(Additional file 2). This novel multiplexed, particle-based, flow
cytometric assay uses anticytokine monoclonal antibodies
linked to microspheres incorporating distinct proportions of
two fluorescent dyes. Five hundred micrograms of total protein
extracts of breast biopsies was used to measure cytokine con-
centration. For each cytokine, eight standards ranging from 2
to 32,000 pg/ml were used, and the minimum detectable dose
was 10 pg/ml. The assay was validated by comparing the
results obtained by bioplex measure of IL-8 with a conventional
enzyme-linked immunosorbent assay measure of IL-8 (Addi-
tional file 3).
Gel shift assays
Gel shift assays were performed as described previously [10].
Briefly, 30,000 count per minute of the [32P]-labelled double-
strand oligonucleotides were combined with 1 μg poly(dI-dC)
and 5 μg total cell extract. The reaction buffer contained 20
mmol/l Hepes (pH 7.9), 1 mmol/l DTT, 50 mmol/l KCl, 10%
glycerol and 2.5 mmol/l MgCl2. Protein-DNA complexes were
separated from the free probe by nondenaturating gel electro-
phoresis with 4% polyacrylamide gels in 0.5 × TBE. We used
the activator protein (AP)-1 consensus oligonucleotide: 3'-
CGCTTGATGAGTCAGCCGGAA-5'. The levels of shifted
complexes were detected and quantified by counting using a
Fujix-Bas 1000 (Fuji Photo-Film, Tokyo, Japan).
Statistical analysis
Data were summarized by frequency for categorical variables
and by median and range for continuous variables. Correlation
between variables (cytokines) was evaluated using the Spear-
man correlation coefficient after log transformation. Associa-
tions between categorical variables were examined using χ2
analyses.
The median levels of expression of analyzed interleukins were
compared using Kruskal-Wallis test according to clinical data
(age, ER, PR, SBR status, pT and pN status) or analysis of var-
iance if possible.
For all statistical analysis, P < 0.05 was considered statisti-
cally significant.
Results
Breast tumours overexpress cytokines
A total of 105 samples of primary unilateral, nonmetastatic
breast carcinomas (Additional file 1) and 13 healthy breast
biopsies were analyzed for cytokine expression at the protein
level (Table 1). This was made possible by the use of a novel
technology that couples enzyme-linked immunosorbent assay
to clourescence-activated cell sorting analysis, which allows
detection of multiple proteins in a single well.
We observed that healthy breast samples expressed very low
levels of cytokines except for IFN-γ and MIP-1β (Table 1). In
contrast, breast tumours exhibited high levels of IL-6, G-CSF
and IFN-γ, and extremely high levels of IL-8, MCP-1 and MIP-
1β. The cytokines IL-5, IL-17 and GM-CSF were not detected
in either normal or tumour sample, whereas IL-1β, IL-2, IL-4, G-
CSF and IL-10 were only detected in breast carcinoma. IL-6,
IL-8, IL-12, IL-13, IFN-γ, MCP-1, MIP-1β and TNF-α were sig-
nificantly more abundant in carcinoma than in normal breast.
The greatest differences in expression between normal breast
tissue and carcinoma occurred in IL-8, MCP-1 and MIP-1β,
which were 60-fold more abundant in carcinoma than in
healthy breast, followed by IL-6, which was about 14-fold over-
expressed in carcinoma. In summary, we found that breast
tumours express higher levels of multiple cytokines than do
normal tissues.
Correlation between cytokines and ER and PR
We next evaluated whether there was any correlation between
cytokine expression and ER levels (Table 2). We observed that
IL-4 and G-CSF were not correlated with ER status. On the
other hand, IL-2, IL-6, IL-8, IL-10, IFN-γ, MCP-1, MIP-1β, TNF-
α and, to a lesser extent, IL-1β and IL-13 were significantly
overexpressed in ER-negative tumours compared with ER-
positive ones, with the greatest differences observed for IL-8
and MCP-1.
We performed the same type of analysis to identify whether
there was any correlation between cytokine levels and PR
expression (Table 2). IL-2 and IL-13 were not correlated with
PR status, whereas IL-1β, IL-6, IL-8, IL-10, IFN-γ, MCP-1, MIP-
1β, TNF-α and, to a lesser extent, IL-4, IL-12 and G-CSF were
more abundant in PR-negative tumours than in PR-positiveBreast Cancer Research    Vol 9 No 1    Chavey et al.
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Table 1
Cytokines are overexpressed in breast cancer
Biological markers Median protein (range; fg/μg) P
Cancer (n = 105) Healthy breast (n = 13)
IL-1β 2.7 (0–260) 0 < 0.0001
IL-2 1.2 (0–42.6) 0 < 0.0001
IL-4 1.7 (0–99.6) 0 < 0.0001
IL-5 0 0
IL-6 17.2 (4.4–26,487) 1.2 (0–52.5) < 0.0001
IL-7 0.7 (0–8.5) 1.1 (0.7–16.9) 0.047
IL-8 68.1 (0–15,890) 1 (0–78.5) < 0.0001
IL-10 0.3 (0–5.6) 0 < 0.0001
IL-12 (p70) 2.3 (0–19.3) 1.4 (0.5–20.4) 0.005
IL-13 4.2 (1.6–394) 1.9 (1.2–21.6) < 0.0001
IL-17 0 0
G-CSF 18.7 (5.3–110) 0 (0–49.2) < 0.0001
GM-CSF 0 0
IFN-γ 27.6 (15.5–1,279) 16.6 (13.6–187) < 0.0001
MCP-1 121 (0–37117) 1.9 (0–45.9) < 0.0001
MIP-1β 559 (42.6–14,439) 8.3 (5.0–142) < 0.0001
TNF-α 7.2 (5.8–121) 1.6 (1.3–23.2) < 0.0001
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; IFN, interferon; MCP, 
monocyte chemoattractant protein; MIP, macrophage inflammatory protein; TNF, tumour necrosis factor.
Table 2
Cytokines are present at high levels in ER-negative and PR-negative breast tumors
Biological marker ER negative (n = 45) ER positive (n = 60) P PR negative (n = 30) PR positive (n = 75) P
IL-1β 3.7 (0–260) 2.2 (0–42.4) 0.031 5.3 (0–194) 2.3 (0–260) 0.008
IL-2 1.7 (0–42.6) 0.9 (0–11.0) 0.003 1.7 (0–6.6) 1.2 (0–42.6) 0.119
IL-4 3.8 (0–20.0) 1.1 (0–99.6) NS 4.6 (0–18.7) 1.1 (0–99.6) 0.040
IL-6 25.4 (7.8–26,487) 13.2 (4.4–619) < 0.001 53.6 (9.9–26,487) 13.7 (4.4–4,312) < 0.001
IL-8 158 (5.0–15,890) 40.5 (0–10,298) < 0.001 505 (7.3–15,890) 48.7 (0–11,281) < 0.001
IL-10 0.6 (0–5.6) 0.2 (0–2.86) 0.003 0.8 (0–5.0) 0.2 (0–5.6) < 0.001
IL-12 (p70) 3.0 (0 -19.3) 2.0 (0–17.2) 0.029 3.1 (0–7.3) 2.0 (0–19.3) 0.024
IL-13 4.3 (3.4–52.6) 4.1 (1.6–394) 0.049 4.3 (3.6–35.5) 4.1 (1.6–394) NS
G-CSF 17.3 (7.1–110) 20.1 (5.3–87.3) NS 24.1 (7.1–110) 17.4 (5.3–103) 0.056
IFN-γ 32.6 (19.4–324) 25.6 (15.5–1,279) < 0.001 33.8 (23.7–324) 25.6 (15.5–1,279) 0.002
MCP-1 210 (14.7–37,117) 80.7 (0–1,543) < 0.001 404 (17.7–37,717) 96.3 (0–1,543) < 0.001
MIP-1β 748 (42.6–14,439) 488 (87.2–10,244) 0.005 1121 (44.6–13,287) 493 (42.6–14,439) 0.001
TNF-α 8.5 (6.1–80.0) 6.9 (5.8–120) < 0.001 8.6 (6.2–37.2) 7.1 (5.8–121) 0.002
Values are expressed as median (range; fg/μg). G-CSF, granulocyte colony-stimulating factor; IL, interleukin; IFN, interferon; MCP, monocyte 
chemoattractant protein; MIP, macrophage inflammatory protein; NS, not significant; TNF, tumour necrosis factor.Available online http://breast-cancer-research.com/content/9/1/R15
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ones. The greatest differences were obtained for IL-8, IL-6 and
MCP-1.
The fact that some cytokines were correlated with either ER or
PR led us to analyze the distribution of all cytokines by com-
bining both factors (Additional file 4). Three categories were
defined, corresponding to true ER negative (ER-/PR-) and ER
positive (ER+/PR+), and intermediate (ER-/PR+ or ER+/PR-)
status. This analysis revealed that IL-1β, IL-2, IL-6, IL-8, IL-10,
IL-12, IFN-γ, MCP-1, MIP-1β and TNF-α were inversely corre-
lated with true ER status. The most abundant cytokines in true
ER negative breast carcinoma were IL-8, MCP-1 and MIP-1β.
Correlation with other clinical parameters
We then evaluated whether cytokine expression could be
linked to clinical parameters such as tumour size, lymph node
status, histological grade, or patient age. The cytokine profile
was not linked to tumour size or to histological type. We did
not observe any correlation between the age of patients at
cancer diagnosis and cytokine expression, except for IL-1β,
which was inversely correlated with the age of the patient: at
age 50 years or younger the median IL-1β level was 3.14 fg/
μg (range 0.2 to 194.2 fg/μg); at age 50–65 years the median
IL-1β level was 2.13 fg/μg (range 0 to 42.4 fg/μg); and at age
above 65 years the median IL-1β level was 1.9 fg/μg (range 0
to 260.6 fg/μg; P = 0.033). Lymph node status was not linked
to any of the analyzed cytokines.
Because ER-negative tumours are generally of higher grade
than ER-positive ones (which was confirmed in our samples;
data not shown), we determined whether cytokine levels could
be correlated with grade. Most of the cytokines that were pref-
erentially present in ER-negative tumours (IL-1β, IL-6, IL-8, IL-
10, IL-12, MCP-1 and MIP-1β) were also more abundant in
high-grade tumours (Table 3).
Another factor that is frequently linked to grade and ER status
is the HER2 level. We observed a correlation between HER2
levels and IL-8 and MIP-1β, which were expressed to a greater
degree in HER2-positive patients; the median (range) IL-8 lev-
els in HER2-negative patients and HER2-positive patients
were 50.8 fg/μg (0 to 15,890 fg/μg) and 192.6 fg/μg (23.7 to
8,357 fg/μg), respectively (P = 0.014); and for MIP-1β the
median (range) levels were 514.9 fg/μg (42.6 to 14,439 fg/
μg) and 976.1 fg/μg (44.6 to 4,978 fg/μg), respectively (P =
0.021). These data suggest that high cytokine levels are asso-
ciated with poor prognostic factors such as high grade, ER-
negative status, and HER2-positive tumours.
AP-1 transcription factors are known to regulate the expres-
sion of many cytokines. To address this issue, we performed
gel shift assays measuring global AP-1 binding to specific
DNA-binding sites. As reported by others [11], AP-1 was more
abundant in ER-negative tumour samples than in ER-positive
ones (P < 0.001). There was also a higher level of HER2 in
AP-1-positive tumours (P = 0.025). In contrast, AP-1 status
was not correlated with PR expression, grade, size of the
tumour and lymph node status. Interestingly, high AP-1 levels
correlated with high levels of expression of several cytokines,
including IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12, IFN-γ, MCP-1 and
TNF-α (Table 4). Among these cytokines, the greatest differ-
ences were observed for IL-8 and MCP-1, which respectively
Table 3
Most cytokines are abundant in high-grade tumors
Biological markers Grade I (n = 17) Grade II (n = 56) Grade III (n = 32) P
IL-1β 0.8 (0–260) 2.6 (0–102) 4.7 (0–194) 0.025
IL-2 0.9 (0–4.6) 1.2 (0–42.6) 1.4 (0–6.6) NS
IL-4 3.4 (0–20.1) 0.6 (0–30.2) 3.9 (0–99.6) 0.037
IL-6 11.7 (7.8–4,312) 14.1 (4.4–190) 30.6 (8.8–26,487) < 0.001
IL-8 43.9 (9.1–11,281) 35.4 (0–8,358) 186 (0.3–15,890) < 0.001
IL-10 0.2 (0–1.6) 0.2 (0–5.6) 0.7 (0–4.6) 0.030
IL-12 (p70) 1.4 (0–5.3) 2.1 (0–19.3) 2.9 (0.7 -17.2) 0.045
IL-13 4.1 (3.4–21.4) 4.2 (3.0–394) 4.2 (1.6–35.5) NS
G-CSF 13.9 (7.1–87.3) 18.9 (5.3–110) 22.2 (9.9–79.2) NS
IFN-γ 26.8 (19.8–270) 25.6 (17.1–1,279) 28.7 (15.5–324) NS
MCP-1 96.3 (22.8–1,208) 91.3 (0–22,451) 201 (24.4–37,117) 0.006
MIP-1β 451 (44.6–2,674) 496 (42.6–14,439) 776 (114–13,287) 0.011
TNF-α 7.15 (5.9–28.0) 7.1 (5.8–120) 7.8 (6.2–37.2) NS
Values are expressed as median (range; fg/μg). G-CSF, granulocyte colony-stimulating factor; IL, interleukin; IFN, interferon; MCP, monocyte 
chemoattractant protein; MIP, macrophage inflammatory protein; NS, not significant; TNF, tumour necrosis factor.Breast Cancer Research    Vol 9 No 1    Chavey et al.
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exhibited 3.9-fold and 2.7-fold higher expression in AP-1-pos-
itive tumours than in AP-1-negative ones (Table 4).
Tumors expressing high levels of IL-8 exhibit high 
vascularization
We next focused our attention on the possible association
between high expression of IL-8 and vascularization. We ana-
lyzed 10 tumours exhibiting high levels of IL-8 and 10 tumours
with low IL-8 content. A microscopic analysis showed that
tumours with high expression of IL-8 were also more vascular-
ized (median of 125 vessels/mm2) than were tumours with low
IL-8 content (48 vessels/mm2; P = 0.0002; Table 5). Overall,
these results suggest that IL-8 expression is associated with
high neovascularization.
Leucocyte infiltration is correlated with high levels of 
cytokines
Because IL-8, MCP-1 and MIP-1β, the most highly expressed
chemokines in cancer tissues, are potent chemotactic mole-
cules, we investigated whether their expression could be cor-
related with tumour leucocyte infiltration. We conducted a
complete immunohistochemical analysis of our collective of
tumour samples using CD3 (B lymphocytes), CD20 (T lym-
phocytes) and CD68 (macrophages) antibodies. A represent-
ative image is shown in Figure 1. Normal breast exhibited no
to low staining, whereas breast cancer tissues exhibited a
complete range of leucocyte infiltration from low to high levels.
Our findings indicate that high levels of IL-8 were correlated
with high macrophage infiltration, whereas strong expression
of MCP-1 and MIP-1β was correlated with robust p1
resence of B lymphocytes, T lymphocytes and macrophages
(Tables 6, 7, 8).
Discussion
It is well known that the interactions of tumour cells with their
microenvironment may affect tumour growth and metastasis
formation. Among these, inflammatory cells and cytokines
were recently suggested to play a key role in breast carcinoma
(for review, see Wilson and Balkwill [4]).
A previous study of breast cancer patients [12] showed that
IL-8 RNA was more abundant in the neoplastic than in the nor-
mal population, whereas no difference was observed for IL-1α,
IL-1β, IL-4, or IL-6. In addition, transcripts for IL-2, IL-4, IL-5, IL-
7, TNF-α and IFN-γ were not detected in either group [12,13].
Increased serum levels of the cytokines IL-6, IL-8 and IL-10
have also been observed in patients suffering from breast can-
cer as compared with healthy women [14,15]. Among the 17
cytokines we analyzed, eight were not detected in normal
breast (IL-1β, IL-2, IL-4, IL-5, IL-10, IL-17, G-CSF and GM-
CSF) and three were absent from breast carcinoma (IL-5, IL-
17 and GM-CSF). With the exception of IL-7, all cytokines that
were present in both tissues were significantly overexpressed
in breast carcinoma.
To date, the correlation between cytokine expression and clin-
ical parameters remains elusive. We observed that IL-1β, IL-6,
IL-8, IL-10, IL-12, MCP-1 and MIP-1β correlated with grade.
IL-8 and MIP-1β were also linked to HER2 status, which is in
agreement with reports demonstrating that IL-8 is regulated by
Table 4
Cytokine levels are correlated to AP-1 expression
Biological markers AP-1 negative (n = 34) AP-1 positive (n = 69) P
IL-1β 1.4 (0–11.5) 3.2 (0–260) 0.006
IL-2 0.4 (0–3.2) 1.4 (0–11) 0.001
IL-4 1.1 (0–99.6) 2.7 (0–30.2) NS
IL-6 12.6 (4.4–70.7) 19.7 (7.8–26,487) 0.001
IL-8 29.6 (0 -778) 115 (1.5–15,890) 0.003
IL-10 0.2 (0–2.6) 0.3 (0– 5.6) 0.004
IL-12 (p70) 1.8 (0 -17.2) 2.7 (0–7.3) 0.044
IL-13 4.2 (3.0–7.2) 4.2 (3.4–394) NS
G-CSF 17.2 (5.3–87.3) 18.5 (7.1–110) NS
IFN-γ 25.4 (15.5–55.5) 28.7 (17.1–1,279) 0.002
MCP-1 54.6 (0–1,208) 148 (14.7–37,117) 0.001
MIP-1β 503 (87.2–8,778) 563 (42.6–14,439) NS
TNF-α 6.9 (6.1–10.9) 7.8 (5.8–121) 0.002
Values are expressed as median (range; fg/μg). AP, activator protein; G-CSF, granulocyte colony-stimulating factor; IL, interleukin; IFN, interferon; 
MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; NS, not significant; TNF, tumour necrosis factor.Available online http://breast-cancer-research.com/content/9/1/R15
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HER2 in breast cancer cell lines [16]. In addition, IL-1β was
inversely correlated to age. IL-1β was previously shown to be
strongly expressed in high-grade invasive breast carcinoma as
compared with in situ ductal carcinoma or benign lesions [17].
In contrast to these results, Green and coworkers [12] did not
observe any correlation between the cytokines IL-1α, IL-1β, IL-
4, IL-6, IL-8, TNF-α, TNF-β, IL-2, IL-5, IL-7 and IFN-γ and
tumour histological grade, patient age or lymph node
metastasis in breast cancer patients, but that study analyzed
only RNA levels.
Of particular note, in our study we found an inverse correlation
between expression of ER and cytokines, which is in agree-
ment the findings of other studies [8,18]. An inverse correla-
tion between IL-8 and ER or PR in breast cancer biopsies has
also been demonstrated [19]. Several studies have reported
that IL-1α, IL-1β, or IL-6 levels correlated inversely with ER lev-
els [20-22]. This inverse correlation between cytokines and
ER status not only may reflect the greater aggressiveness of
this subtype of breast tumours but it could also be the result
of a direct regulation of cytokine expression by ER. Several
reports have demonstrated a direct downregulation of
cytokines by ER in different organs. This is not only the case
for IL-6 [23,24] and IL-8 [8,18] but also for IL-1β (for review,
see Pfeilschifter and coworkers [24]), IL-2 [25], IL-10 [26], IL-
12 (for review, see Salem [27]), GM-CSF [24], IFN-γ [28,29],
MCP-1 [30,31] and TNF-α [24]. PR is also known to downreg-
ulate the expression of a number of cytokines, including IL-1β
[32], IL-6 [30,33], IL-8 [34], MCP-1 [32,35] and TNF-α [32],
which is in agreement with our findings.
According to our work, Th1 cytokines (IL-2 and IFN-γ) and Th2
cytokines (such as IL-4 and IL-5) are not the major cytokines
produced by tumours. However, several cytokines produced
by monocytes (IL-1β, IL-6 and MCP-1) or macrophages (such
as IL-1β, IL-6, IL-8, MIP-1β and TNF-α) are highly expressed by
the tumour. We observed that tumours displaying high levels
of IL-8 exhibited significantly greater vascularization. A role for
IL-8 in breast cancer angiogenesis has also been suggested
by in vitro studies [18], but to our knowledge ours is the first
study to report an association between IL-8 levels and angio-
genesis in breast cancer samples.
We found that tumours expressing high levels of MCP-1 and
MIP-1β had greater B lymphocyte, T lymphocyte and macro-
phage content than did tumours expressing low levels of these
chemokines. Similarly, robust expression of IL-8 was corre-
lated with marked macrophage infiltration. Our results are thus
in agreement with previous studies that showed a correlation
between the number of tumour associated macrophages and
IL-6, IL-8 or MCP-1 levels in breast and cervical cancers [36-
38]. On the other hand, the correlation between MIP-1β and
macrophage infiltration has not been reported to date, or has
the association of high levels of MCP-1 and MIP-1β with the
presence of B and T lymphocytes in breast carcinoma. The
precise role played by leucocytes in tumours remains to be
elucidated in larger studies, which may determine whether
they contribute to tumour growth.
Conclusion
The pattern of expression of multiple cytokines in breast can-
cer tissues that we report is the first step in elucidating the
involvement of cytokines in breast cancer. Our data suggest
that cytokines could be involved in the aggressiveness of ER-
negative breast tumours. In addition, robust expression of IL-8,
MCP-1 and MIP-1β, which are the three major chemokines
present in breast tumours, is correlated with marked leucocyte
infiltration. We therefore believe that our work provides
justification for further studies to determine more precisely the
role played by these cytokines in breast cancer.
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Table 5
IL-8 expression is correlated to angiogenesis
IL-8 Vessels/mm2
-4 8
-7 2
-5 3
-4 4
-3 0
-N D
-5 7
-4 6
-6 3
-2 0
+ 244
+ 128
+7 8
+ 279
+ 116
+ 209
+ 124
+9 4
+8 1
+ 359
Vessel density in a series of tumors with high (+; n = 10) and low (-; 
n = 10) expression of IL-8. Haematoxylin and eosin saffron stain was 
used. ND, not detectable.Breast Cancer Research    Vol 9 No 1    Chavey et al.
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Table 6
IL-8 expression and leucocyte infiltration
Antibody Staining n IL-8 mediana IL-8 minimuma IL-8 maximuma Pb
CD3 0 54 47.6 0 11,281 0.17
1 36 67.7 0.3 15,890
2 11 289.7 27.6 10,298
3 4 145.0 14.9 4,408
CD20 0 74 59.2 0 15,890 0.42
1 27 219.9 1.5 10,298
2 3 165.2 14.9 4,408
3 1 124.8 124.8 124.8
CD68 0 5 23.6 0.6 146.7 0.0011
1 59 48.6 0 15,890
2 32 108.6 5.6 11,281
3 9 289.9 14.9 10,298
Values are expressed as fg/μg. bBy analysis of variance. IL, interleukin.
Table 7
MCP-1 expression and leucocyte infiltration
Antibody Staining n MCP-1 mediana MCP-1 minimuma MCP-1 maximuma Pb
CD3 0 54 110.5 0 1,543 0.0001
1 36 107.9 23.3 8,479
2 11 278.3 45.5 22,451
3 4 3307 196.5 37,117
CD20 0 74 110.3 0 8,478 0.0002
1 27 192.9 23.35 22,451
2 3 3185 196.5 37,117
3 1 3439 3430 3,430
CD68 0 5 40.9 7.0 167.4 0.0016
1 59 102.6 8.0 8,479
2 32 137.9 0 37,117
3 9 478.3 45.5 3,430
Values are expressed as fg/μg. bBy analysis of variance. MCP, monocyte chemoattractant protein.
Table 8
MIP-1β expression and leucocyte infiltration
Antibody Staining n MIP-1β mediana MIP-1β minimuma MIP-1β maximuma Pb
CD3 0 54 472.5 42.6 12835 < 0.0001
1 36 560.7 44.6 10685
2 11 2702 274.5 14439
3 4 6757 1226 13287
CD20 0 74 495.9 42.6 14439 < 0.0001
1 27 745.3 44.6 10685
2 3 4394 1226 9121
3 1 13287 13287 13287
CD68 0 5 342.4 223.4 498.7 < 0.0001
1 59 458 42.6 12835
2 32 739.8 134.3 14439
3 9 3095 589.3 13287
Values are expressed as fg/μg. bBy analysis of variance. MIP, macrophage inflammatory protein.Available online http://breast-cancer-research.com/content/9/1/R15
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